KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Profit After Tax (2016 - 2026)

Halozyme Therapeutics has reported Profit After Tax over the past 17 years, most recently at $150.0 million for Q1 2026.

  • Quarterly Profit After Tax rose 27.06% to $150.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $348.8 million through Mar 2026, down 28.13% year-over-year, with the annual reading at $316.9 million for FY2025, 28.64% down from the prior year.
  • Profit After Tax was $150.0 million for Q1 2026 at Halozyme Therapeutics, up from -$141.6 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $175.2 million in Q3 2025 and troughed at -$141.6 million in Q4 2025.
  • The 5-year median for Profit After Tax is $81.8 million (2023), against an average of $82.0 million.
  • Year-over-year, Profit After Tax surged 229.53% in 2023 and then crashed 203.34% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $57.7 million in 2022, then surged by 47.98% to $85.4 million in 2023, then surged by 60.46% to $137.0 million in 2024, then crashed by 203.34% to -$141.6 million in 2025, then skyrocketed by 205.97% to $150.0 million in 2026.
  • Per Business Quant, the three most recent readings for HALO's Profit After Tax are $150.0 million (Q1 2026), -$141.6 million (Q4 2025), and $175.2 million (Q3 2025).